Our InnoSolve and Innofil3D PLA used by University of Cambridge Post-Doctoral Researcher Dr. Daniel Markl and Chemical Engineering professor Dr. Axel Zeitler.
We just wanted to share this article with you; concerning the High Accuracy of Medicinal 3D Printing in combination with Innofil3D PVA (InnoSolve) and PLA.
A study led by University of Cambridge Post-Doctoral Researcher Dr. Daniel Markl and Chemical Engineering professor Dr. Axel Zeitler demonstrated the viability of 3D printing technology in structuring and printing active pharmaceutical ingredient (API) formulations.
Over the past few years, researchers and institutions have been actively looking into the usability of 3D printers in creating medicine. We have seen companies such as Aprecia Pharmaceuticals, which was approved by the US Food and Drug Administration (FDA) to produce and distribute SPRITAM levetiracetem tablets manufactured using enterprise-grade 3D printers.
To eliminate any potential variables that may affect the evaluation of 3D printed dosage forms, researchers performed the experiment with two solutions: polyvinyl alcohol (PVA) and polylactic acid (PLA), with both materials supplied by Innofil3D. PVA and PLA-based 3D printed drugs were then examined by XμCT and TPI.
The original post on 3DPrint.com; Study Shows High Accuracy of Medicinal 3D Printing
The original study can be found on; Springer.com – Analysis of 3D Prints by X-ray Computed Microtomography and Terahertz Pulsed Imaging